A sales partner offered a ray of hope that this company couldn't for itself.
Zacks Investment Research on MSN
CRSP posts wider-than-expected loss in Q4, sales miss estimates
CRISPR Therapeutics CRSP reported a fourth-quarter 2025 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a ...
The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics ...
2026 could be a big year for this company.
Opportunity knocks thrice for the iconic growth investor.
CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...
Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter ...
CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...
Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results